Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIXT Bioxytran	$0.09 -4.3%	$0.11	$0.06 ▼ $0.23	$8.37M	1.78	75,770 shs	37,250 shs
CVM CEL-SCI	$9.45 +15.5%	$3.59	$1.98 ▼ $39.30	$50.28M	0.3	380,418 shs	521,184 shs
FGEN FibroGen	$6.89 -0.4%	$6.82	$4.50 ▼ $21.94	$27.97M	0.76	39,756 shs	14,398 shs
RNTX Rein Therapeutics	$1.11 -4.7%	$1.62	$1.05 ▼ $4.40	$26.85M	1.31	46,174 shs	24,881 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIXT Bioxytran	-4.26%	+4.65%	-8.35%	-41.21%	-24.87%
CVM CEL-SCI	+15.53%	+15.24%	+275.00%	+25.50%	-72.25%
FGEN FibroGen	-0.43%	-7.52%	+31.24%	-17.34%	-48.97%
RNTX Rein Therapeutics	-4.72%	-23.97%	-27.92%	-39.01%	+110,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BIXT Bioxytran	0.31 of 5 stars	0.0	3.0	0.0	0.0	0.6	1.7	0.0
CVM CEL-SCI	1.2111 of 5 stars	0.0	2.0	0.0	0.0	4.3	1.7	0.6
FGEN FibroGen	4.4046 of 5 stars	3.3	5.0	0.0	4.7	1.1	3.3	0.6
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIXT Bioxytran	0.00	N/A	N/A	N/A
CVM CEL-SCI	0.00	N/A	N/A	N/A
FGEN FibroGen	2.50	Moderate Buy	$250.00	3,528.45% Upside
RNTX Rein Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest BIXT, CVM, RNTX, and FGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/13/2025	FGEN FibroGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$250.00 ➝ $250.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIXT Bioxytran	N/A	N/A	N/A	N/A	($0.02) per share	N/A
CVM CEL-SCI	N/A	N/A	N/A	N/A	$0.15 per share	N/A
FGEN FibroGen	$29.62M	0.94	N/A	N/A	($50.89) per share	-0.14
RNTX Rein Therapeutics	N/A	N/A	$0.43 per share	2.60	$0.43 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIXT Bioxytran	-$2.37M	-$0.03	N/A	∞	N/A	N/A	N/A	-2,077.16%	N/A
CVM CEL-SCI	-$26.92M	-$12.61	N/A	N/A	N/A	N/A	-238.05%	-104.65%	N/A
FGEN FibroGen	-$47.58M	-$2.50	N/A	N/A	N/A	-9.73%	N/A	-24.77%	8/5/2025 (Estimated)
RNTX Rein Therapeutics	-$62.88M	-$2.86	N/A	N/A	N/A	N/A	-86.07%	-31.11%	N/A

Latest BIXT, CVM, RNTX, and FGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	FGEN FibroGen	-$0.09	N/A	N/A	N/A	$2.88 million	N/A
5/15/2025	Q1 2025	BIXT Bioxytran	N/A	-$0.02	N/A	-$0.02	N/A	N/A
5/15/2025	Q1 2025	RNTX Rein Therapeutics	-$0.21	-$0.25	-$0.04	-$0.25	N/A	N/A
5/12/2025	Q1 2025	FGEN FibroGen	$0.75	-$4.00	-$4.75	$0.05	$2.00 million	$2.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIXT Bioxytran	N/A	N/A	N/A	N/A	N/A
CVM CEL-SCI	N/A	N/A	N/A	N/A	N/A
FGEN FibroGen	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIXT Bioxytran	N/A	N/A	N/A
CVM CEL-SCI	0.66	1.07	1.09
FGEN FibroGen	N/A	2.02	1.98
RNTX Rein Therapeutics	N/A	1.39	1.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIXT Bioxytran	N/A
CVM CEL-SCI	12.08%
FGEN FibroGen	72.71%
RNTX Rein Therapeutics	90.89%

Insider Ownership

Company	Insider Ownership
BIXT Bioxytran	70.00%
CVM CEL-SCI	9.93%
FGEN FibroGen	3.07%
RNTX Rein Therapeutics	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIXT Bioxytran	2	88.99 million	26.70 million	Not Optionable
CVM CEL-SCI	43	5.32 million	64.67 million	Optionable
FGEN FibroGen	570	4.04 million	3.92 million	Optionable
RNTX Rein Therapeutics	9	23.05 million	21.02 million	N/A

BIXT, CVM, RNTX, and FGEN Headlines

Recent News About These Companies

Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing

July 30 at 4:59 PM | finance.yahoo.com

RNTX - Rein Therapeutics Inc Dividends - Morningstar

June 26, 2025 | morningstar.comM

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

June 24, 2025 | prnewswire.com

US FDA puts on hold Rein Therapeutics' lung disease drug trial

June 12, 2025 | reuters.com

RNTX Rein Therapeutics Inc.

June 1, 2025 | seekingalpha.com

Rein Therapeutics, Inc.: Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 27, 2025 | finanznachrichten.de

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 27, 2025 | prnewswire.com

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

May 19, 2025 | prnewswire.com

Rein Therapeutics, Inc.: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 16, 2025 | finanznachrichten.de

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025 | prnewswire.com

Rein Therapeutics begins trial for idiopathic pulmonary fibrosis treatment

May 13, 2025 | msn.com

Rein Therapeutics, Inc.: Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 12, 2025 | finanznachrichten.de

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 12, 2025 | prnewswire.com

Rein Therapeutics to integrate Qureight’s platform in trial of IPF treatment

May 2, 2025 | msn.com

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

May 1, 2025 | prnewswire.com

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

April 30, 2025 | prnewswire.com

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

April 28, 2025 | prnewswire.com

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

April 23, 2025 | prnewswire.com

Rein Therapeutics reports IPF and PASC-F treatment progress

April 17, 2025 | uk.investing.com

Rein Therapeutics’ LTI-2355 peptide shows therapuetic potential in study

April 16, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIXT, CVM, RNTX, and FGEN Company Descriptions

Bioxytran OTCMKTS:BIXT

$0.09 0.00 (-4.26%)

As of 08/1/2025 02:08 PM Eastern

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.

CEL-SCI NYSE:CVM

$9.45 +1.27 (+15.53%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$9.29 -0.16 (-1.69%)

As of 08/1/2025 07:58 PM Eastern

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

FibroGen NASDAQ:FGEN

$6.89 -0.03 (-0.43%)

Closing price 08/1/2025 03:59 PM Eastern

Extended Trading

$6.85 -0.04 (-0.58%)

As of 08/1/2025 04:51 PM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Rein Therapeutics NASDAQ:RNTX

$1.11 -0.06 (-4.72%)

As of 08/1/2025 03:59 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time